NX‐0255 AND NX‐1607, SMALL MOLECULE INHIBITORS OF CBL‐B, ARE EFFICACIOUS IN COMBINATION WITH ADOPTIVE CELL THERAPY OR RITUXIMAB IN PRECLINICAL MOUSE MODELS OF LYMPHOMA von Gallotta, M., Romo, J. Gomez, Ranucci, S., Tenn‐McClellan, A., Borodovsky, A., Stokes, J., Lotze, M. T., Sands, A. T., Hansen, G. M., Rountree, R., Guiducci, C.

Volltext

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B C... von Robbins, Daniel W., Noviski, Mark A., Tan, Ying Siow, Konst, Zef A., Kelly, Aileen, Auger, Paul, Brathaban, Nivetha, Cass, Robert, Chan, Ming Liang, Cherala, Ganesh, Clifton, Matthew C., Gajewski, Stefan, Ingallinera, Timothy G., Karr, Dane, Kato, Daisuke, Ma, Jun, McKinnell, Jenny, McIntosh, Joel, Mihalic, Jeff, Murphy, Brent, Panga, Jaipal Reddy, Peng, Ge, Powers, Janine, Perez, Luz, Rountree, Ryan, Tenn-McClellan, Austin, Sands, Arthur T., Weiss, Dahlia R., Wu, Jeffrey, Ye, Jordan, Guiducci, Cristiana, Hansen, Gwenn, Cohen, Frederick

Volltext

Abstract 1595: Small molecule inhibition of the ubiquitin ligase CBL-B results in potent T and NK cell mediated anti-tumor response von Rountree, Ryan, Cohen, Frederick, Tenn-McClellan, Austin, Borodovsky, Alexandra, Gallotta, Marilena, Stokes, Jennifer, Romo, Jose Gomez, Karim, Chris, Hansen, Gwenn M., Guiducci, Cristiana, Sands, Arthur, Gosling, Jennifa

Volltext

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts von Zhang, Deyi, Harris, Hailey M., Chen, Jonathan, Judy, Jen, James, Gabriella, Kelly, Aileen, McIntosh, Joel, Tenn-McClellan, Austin, Ambing, Eileen, Tan, Ying Siow, Lu, Hao, Gajewski, Stefan, Clifton, Matthew C., Yung, Stephanie, Robbins, Daniel W., Pirooznia, Mehdi, Skånland, Sigrid S., Gaglione, Erika, Mhibik, Maissa, Underbayev, Chingiz, Ahn, Inhye E., Sun, Clare, Herman, Sarah E. M., Noviski, Mark, Wiestner, Adrian

Volltext

Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies von Robbins, Daniel W, Noviski, Mark, Rountree, Ryan, Tan, May, Brathaban, Nivetha, Ingallinera, Timothy, Karr, Dane E, Kelly, Aileen, Konst, Zef, Ma, Jun, Tenn-McClellan, Austin, McKinnell, Jenny, Perez, Luz, Guiducci, Cristiana, Hansen, Gwenn, Sands, Arthur

Volltext

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies von Robbins, Daniel W, Kelly, Aileen, Tan, May, McIntosh, Joel, Wu, Jeffrey, Konst, Zef, Kato, Daisuke, Peng, Ge, Mihalic, Jeff, Weiss, Dahlia, Perez, Luz, Tung, Jennifer, Kolobova, Anna, Borodovsky, Sasha, Rountree, Ryan, Tenn-McClellan, Austin, Noviski, Mark, Ye, Jordan, Basham, Steve, Ingallinera, Timothy, McKinnell, Jenny, Karr, Dane E, Powers, Janine, Guiducci, Cristiana, Sands, Arthur

Volltext

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies von Kelly, Aileen, Robbins, Daniel W, Tan, May, Tenn-McClellan, Austin, McIntosh, Joel, Wu, Jeffrey, Konst, Zef, Kato, Daisuke, Perez, Luz, Tung, Jennifer, Kolobova, Anna, Ingallinera, Timothy, McKinnell, Jenny, Weiss, Dahlia, Noviski, Mark, Ye, Jordan, Peng, Ge, Cardozo, Mario, Mihalic, Jeff, Basham, Steve, Rountree, Ryan, Karr, Dane E, Bence, Neil, Zapf, Christoph W, Sands, Arthur T

Volltext

Abstract 2696: Genetic and pharmacologic evaluation of the ubiquitin ligase CBL-B as a small-molecule, tumor immunotherapy target von Gosling, Jennifa, Rountree, Ryan, Taherbhoy, Asad, Wang, Chenbo, Cummins, Thomas, Cohen, Frederick, Tanaka, Hiroko, Weiss, Dahlia, Cardozo, Mario, Karim, Christopher, Tan, May, Juan, Joseph, Tenn-McClellan, Austin, Soly, Szerenke Kiss von, Sheung, Julie, Boyle, Kathleen, Dhamnaskar, Ketki, Kurylo, Katherine, Bruffey, Jilliane, McKinnell, Jennifer, Karr, Dane, Christianson, Andria, Vries, Anne-Renee Van Der Vuurst de, Sivakumar, Pallavur, Gallop, Mark, Barsanti, Paul A., Saha, Anjanabha, Bence, Neil F., Zapf, Christoph W.

Volltext

Abstract 573: Ex-vivo inhibition of CBL-B with a novel small molecule inhibitor, NX-0255, enhances persistence and anti-tumor activity of adoptively transferred CD8+ T cells in mou... von Gallotta, Marilena, Romo, Jose Gomez, Borodovsky, Alexandra, Tenn-McClellan, Austin, Stokes, Jennifer, Gosling, Jennifa, Hansen, Gwenn M., Sands, Arthur, Rountree, Ryan, Guiducci, Cristiana

Volltext

Abstract 1126: Concurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing von Noviski, Mark A., Ma, Jun, Lee, Ernestine, Brathaban, Nivetha, Tan, May, Perez, Luz, Robbins, Daniel W., Tenn-McClellan, Austin, Powers, Janine, Hansen, Gwenn, Guiducci, Cristiana, Rountree, Ryan

Volltext

Abstract 3423: NX-2127: A first-in-class clinical stage degrader of BTK and IKZF1/3 for the treatment of patients with B cell malignancies von Mihalic, Jeffrey T., Brathaban, Nivetha, Bravo, Brandon, Ingallinera, Timothy, Kato, Daisuke, Lu, Hao, Ma, Jun, McIntosh, Joel, Tenn-McClellan, Austin, Mukerji, Ratul, Noviski, Mark A., Peng, Ge, Perez, Luz, Rountree, Ryan, Tan, May, Wu, Jeffrey, Ye, Jordan, Yung, Stephanie

Volltext